NCT05155020终止2 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma
Akeso19 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2022年2月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 1
- 试验地点
- 19
- 主要终点
- Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline at week 12.
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.
详细描述
This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study. The purpose of this study is to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma and not adequately controlled with current stable medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers.Subjects will be randomized to receive AK120 or placebo subcutaneous injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged ≥18 years old and ≤75 years old;
- •Asthma was diagnosed ≥ 12 months before screening, current stable treatment with medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers ≥ 3 months;
- •Blood eosinophil≥ 200 cells per microliter within 6 months before screening;
- •During the screening, 40% of the predicted normal value < pre-bronchodilator FEV1 < 80% of the predicted normal value, within 12 months before randomization, reversible airflow restriction was recorded;
- •Asthma was inadequately controlled;
- •For women with childbearing potential, they are not pregnant or lactating, and the subjects and their partners voluntarily take effective contraceptive measures judged by the investigators during the treatment and at least 3 months after last dose.
排除标准
- •Subjects with lung diseases other than asthma, which may affect the subject's health or end point evaluation of the study;
- •Subjects had severe exacerbation events or systemic glucocorticoids usage within 1 month before randomization;
- •Respiratory tract infection and any serious infection within 1 month before randomization;
- •Subjects with parasitic infection, active tuberculosis infection, Hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis positive confirmation test;
- •Known or suspected history of immunosuppression;
- •History of malignant tumors;
- •A history of smoking: those who had quit smoking for ≤ 6 months before screening, or smoking history > 10 pack per year;
- •Previous treatment with interleukin-4 (IL-4) or interleukin-13 (IL-13) inhibitors, and inadequate washout period of other biologic therapy;
- •Allergen immunotherapy within 3 months before randomization;
- •Progressive or uncontrolled other diseases or any other conditions or abnormal laboratory tests for which the investigator assess that the subjects are not suitable to enrol in the study.
结局指标
主要结局
Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline at week 12.
时间窗: At week 12
次要结局
- Changes in asthma control questionnaire (ACQ-5) scores from baseline to week 32.(Baseline to Week32)
- Annualized rate of severe exacerbation events within 24 weeks.(Baseline to Week24)
- Annualized rate of severe exacerbation events within 32 weeks.(Baseline to Week32)
- Percentage change in pre-bronchodilator FEV1 from baseline to week 32.(Baseline to Week32)
- Safety assessment: treatment-emergent adverse events (TEAE), serious adverse events (SAE) .(Baseline to Week32)
- Change in pre-bronchodilator FEV1 from baseline to week 32.(Baseline to Week32)
- Change in fractional exhaled nitric oxide (FeNO) from baseline to week 32.(Baseline to Week32)
- Change in standardized version of the asthma quality of life (AQLQ-s) scores from baseline at week 12 and 24.(at week 12,week 24)
- Immunogenicity assessment: number and percentage of subjects with detectable anti-AK120 antibody (ADA).(Baseline to Week32)
- Change in post-bronchodilator FEV1 from baseline to week 32.(Baseline to Week32)
- Pharmacokinetics (PK): AK120 concentration at different time points.(Baseline to Week32)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
2 期
A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT02590965Hutchison Medipharma Limited91
进行中（未招募）
2 期
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot UlcersDiabetic Foot UlcersNCT06189638Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.90
已完成
2 期
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe PsoriasisPsoriasisNCT05096364Akeso251
已完成
2 期
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque PsoriasisModerate to Severe Plaque PsoriasisNCT06109818Beijing InnoCare Pharma Tech Co., Ltd.129
进行中（未招募）
2 期
A Study of Mosliciguat in PH-ILDLung DiseasesVascular DiseasesCardiovascular DiseasesFibrosisInterstitial Lung DiseasePulmonary HypertensionNCT06635850Pulmovant, Inc.135